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Application of industrial treatments to donor human milk:
influence of pasteurization treatments, storage temperature,
and time on human milk gangliosides
Jaime Salcedo1, Sercan Karav2, Annabelle Le Parc3,5, Joshua L. Cohen1, Juliana M. L. N. de Moura Bell1, Adam Sun3,
Matthew C. Lange 1 and Daniela Barile1,4
Donor milk is the best option when mother’s own milk is unavailable. Heat treatments are applied to ensure donor milk safety. The
effects of heat treatments on milk gangliosides—bioactive compounds with beneficial antibacterial, anti-inflammatory, and
prebiotic roles—have not been studied. The most abundant gangliosides in non-homogenized human milk were characterized and
quantified by liquid chromatography–mass spectrometry (LC–MS)/MS before and after pasteurization treatments mimicking
industrial conditions (63 °C/30 min, 72 °C/15 s, 127 °C/5 s, and 140 °C/6 s). Ganglioside stability over a 3-month period was assessed
following the storage at 4 and 23 °C. Independent of the heat treatment applied, gangliosides were stable after 3 months of storage
at 4 or 23 °C, with only minor variations in individual ganglioside structures. These findings will help to define the ideal processing
and storage conditions for donor milk to maximize the preservation of the structure of bioactive compounds to enhance the health
of fragile newborns. Moreover, these results highlight the need for, and provide a basis for, a standardized language enabling
biological and food companies, regulatory agencies, and other food stakeholders to both annotate and compute the ways in which
production, processing, and storage conditions alter or maintain the nutritive, bioactive, and organoleptic properties of ingredients
and foods, as well as the qualitative effects these foods and ingredients may have on conferring phenotype in the consuming
organism.
npj Science of Food  (2018) 2:5 ; doi:10.1038/s41538-018-0013-9
INTRODUCTION
Breastfeeding is generally considered the optimal infant nutrition
for the first 6 months of life. However, if breastfeeding is not
possible, international authorities (World Health Organization
(WHO), American Academy of Pediatrics, European Society of
Pediatric Gastroenterology, Hepatology and Nutrition) recom-
mend using pasteurized donor breast milk as the most adequate
alternative.1 Despite the efforts made to humanize the infant
formula, its composition lacks many of the immunological and
protective factors—oligosaccharides and glycolipids, among
others—present in human milk.2,3 Characterization and quantifi-
cation of the bioactive components found in milks, together with
the characterization and quantification of the processing condi-
tions that alter them, provide baseline profiles for formula makers
to mimic the nutrient and bioactive properties found in human
milk.
Donor milk affords benefits beyond simple provision of
nutrients for newborns, including protection from infection, lower
incidence of necrotizing enterocolitis, improved food tolerance,
and better long-term neurological development.4–7 The main
concern regarding donor milk is its microbiological safety, as
preterm infants are particularly susceptible to bacterial infections.
Current official protocols include pasteurization and freezer
storage at –20 °C to eliminate hazards for newborns and preserve
bioactive compounds. Several studies evaluated the effect of heat
treatment and storage conditions on human milk components:
Holder pasteurization (63 °C/30min) and conventional pasteuriza-
tion (75 °C/15 s) do not increase lipid oxidation, but they do
diminish glutathione oxidase and glutathione peroxidase activ-
ities, therefore, decreasing the total antioxidant potential in the
milk.8 The literature reports conflicting results regarding the
effects of storage conditions on milk compounds. Some authors
reported that fatty acids are stable at room temperature (RT), 4,
–20, or –80 °C,9 for 12 months. Additionally, oxidative status and
lipase activity are unchanged during the storage at –20 °C.
However, others reported a decrease in total fat content, lactose,
and oligosaccharides overtime in pasteurized milk stored at –20 °
C.10 Not only does milk composition vary depending on the heat
treatment or storage conditions, but its biological properties are
also modified. Previous works reported that, compared to
untreated milk, the bactericidal activity of human milk against
Escherichia coli decreased significantly, when using the conven-
tional treatments employed by milk banks.11 Decreases in
bactericidal activity were also observed in non-pasteurized milk
after 3 months storage at –20 and –80 °C12 but not after 1 month
at –80 °C.
Although, human milk oligosaccharides have gained impor-
tance as new bioactive compounds,13 other glycoconjugates, such
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as glycolipids, which may contribute to breast milk protective
functions, have been neglected. Recent publications reported that
in the newborn, glycolipids play key roles in development, such as
brain formation, immune response maturation, and protection
from allergy.7,14–17 Human milk contains glycolipids primarily as
gangliosides almost exclusively associated with the milk fat
globule membrane.18 These gangliosides can be defined as
glycosphingolipids, as they are composed of a sphingoid base
linked to a fatty acid by an amide linkage (ceramide) bound to an
oligosaccharide chain of variable size containing one or more sialic
acid moieties.18 The possible combinations of the constituent
monosaccharides, sialic acid molecules, and ceramide structures
give rise to countless types of gangliosides varying in composition,
structure, and linkages. Thus, gangliosides vary widely in both
content and profile in milk during lactation.
The total ganglioside content is at its highest in colostrum, with
an average value of 11 mg/L lipid-bound sialic acid, and its
concentration decreases during lactation until it becomes barely
detectable in mature human milk (0.3 mg/L lipid-bound sialic
acid).3 During the first few days of lactation, GD3 (Neu5Ac α2-8
Neu5Ac α2-3 Gal β1-4Glc β1-1 ceramide) is the most abundant
ganglioside in human milk, comprising almost 65% of total
gangliosides, followed by GM3 (Neu5Ac α2-3 Gal β1-4Glc β1-1
ceramide, 25% of the total). As lactation advances, their relative
abundance reverses, with GM3 being the most abundant in
mature milk (85% of total gangliosides) followed by GD3 (9%).
Throughout the entire lactation period, other gangliosides are
detected in lower concentration: O-acetyl GD3, GM2 (GalNAcβ1-4
(Neu5Ac α2-3)Galβ1-4Glc β1-1 ceramide), and GM1 (Galβ1-
3GalNAcβ1-4[Neu5Ac α2-3] Galβ1-4Glcβ1-1 ceramide).3
Due to the low content of gangliosides (ppm level) and to the
high-structural diversity of those compounds, the development of
a fast and accurate methodology for their determination is
challenging. The classic methodology for quantifying the total
amount of gangliosides, based on the resorcinol-HCl reagent and
high-performance thin-layer chromatography coupled to densito-
metric detection19 is laborious, time-consuming, and does not
allow the full elucidation of their structures.18 Recently, our group
developed a method to identify and quantify gangliosides in
human and bovine milk by LC–MS/MS and ultrahigh-performance
liquid chromatography-quadrupole time-of-flight (UHPLC-
qTOF).20,21 With the introduction of MS techniques, it is possible
not only to characterize both glycan and ceramide lipid portions,
but also to accurately quantitate each ganglioside.21
As studies evaluating the effects of heat treatments on human
milk ganglioside content and profile are lacking, the present work
was aimed at the identification and quantitation of the structural
changes of the main gangliosides in human milk after being
subjected to different pasteurization treatments and determina-
tion of their stability under different storage conditions. This study
will help to define the ideal processing and storage conditions for
donor milk to preserve the structure of bioactive compounds for
enhancing the health of fragile newborns.
RESULTS
The concentration of GM3, GD3, and total gangliosides in the non-
treated human milk is 9.06, 5.66, and 14.72 mg/L, respectively. The
direct effect of each heat treatment, evaluated by measuring the
glycolipid concentration just after heat treatment, is shown in
Table 1. Only the concentration of GM3 statistically increases
when human milk is subjected to HT-2, rest of the conditions are
not showing any effect on the compounds analyzed. During the
90 days study, the total ganglioside content, considered as the
sum of GM3 and GD3, ranged between 14.40 and 15.55 mg/L
(Table 2), while individual GM3 and GD3 contents varied between
8.83 and 9.69mg/L, and 5.47 and 5.86 mg/L for GM3 and GD3,
respectively.
When the effect of the different heat treatment over ganglio-
sides concentration during 90 days was assessed at two storage
conditions (Tables 2 and 3), neither time nor temperature
significantly affected ganglioside content during the 90 days of
treatment (Fig. 1). However, heat treatment significantly altered
both total and individual ganglioside contents. HT-2 increased the
content of GM3, GD3, and total gangliosides compared with
unheated milk (Fig. 1).
Although, the variation in terms of content were not statistically
significant during storage time, there was a qualitative shift in the
ceramide component of individual gangliosides (Figs. 2 and 3).
High-temperature treatments increased the formation of GD3
(d35:1), GD3(d36:1), GM3(38:1), G3(d39:1), and GM3(43:1), whereas
at lower temperatures the ganglioside profile was similar to that of
unheated milk. During storage, there were minor variations in the
gangliosides profile depending on the heat treatment and storage
time. The ganglioside species profile of unheated milk remained
stable when stored at 4 °C, but the GM3(d40:1) and GM3(d41:1)
species were reduced when samples were stored at 23 °C. When
milk was heat treated, ganglioside GD3 was more stable than GM3
after 3 months of storage, the GD3(d34:1) species decreased when
milk was subjected to HT-2 (HTST). This decrease in GD3 (d34:1)
species became greater when the sample was stored at 23 °C (Fig.
2b). In contrast, the effect of storage time on the GM3 species was
more variable than temperature effects, GM3(d34:1), GM3(d40:1),
and GM3(d41:1) were the most affected (Fig. 3a). It is noteworthy
that there were minimal variations in milk GM3 and GD3 over
storage time independent of storage temperature. HM subjected
to HT-4 showed minimal variations in both the GM3 and
GD3 species during storage independent of storage conditions.
DISCUSSION
The present work aims to evaluate if the glycolipid content in non-
homogenized human milk remain stable overtime independently
of storage and temperature conditions (i.e., during 90 days
refrigerated at 4 °C or stored at RT). Furthermore, the four heat
treatments most commonly used by the milk banks and by the
dairy industry (Holder pasteurization, high-temperature-short-time
pasteurization (HTST), extended shelf-life (ESL), and ultrahigh-
Table 1. Concentration of GM3, GD3, and total gangliosides in human milk subjected or not to different heat treatments at day 0 posttreatment
No heat treatment HT-1 HT-2 HT-3 HT-4
[GM3] (mg/L) 9.05 ± 0.13 9.25 ± 0.36 9.50 ± 0.11* 9.25 ± 0.21 9.30 ± 0.14
[GD3] (mg/L) 5.66 ± 0.24 5.70 ± 0.41 5.84 ± 0.33 5.69 ± 0.29 5.76 ± 0.43
Total GG (mg/L) 14.72 ± 0.15 14.94 ± 0.76 15.34 ± 0.27 14.94 ± 0.29 15.06 ± 0.44
Results expressed as mg ganglioside/L human milk (n= 3). Results expressed as mean ± standard deviation (n= 3)
HT-1 Holder pasteurization (63 °C/30 min), HT-2 standard high-temperature-short-time pasteurization (72 °C/15 s), HT-3 extended shelf-life protocol (127 °C/5 s),
HT-4 ultrahigh-temperature pasteurization (140 °C/6 s)
* Indicates statistical differences with no heat-treated sample (Tukey’s test) (p < 0.05)
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temperature (UHT)) were evaluated to study their suitability for
human milk processing in terms of glycolipid content and stability.
Human milk glycolipids content is known to vary widely
depending on the lactation stage, diet, and ethnicity, with
reported concentrations for GM3 and GD3 ranging from 2.8 mg/
L to 14.3 mg/L for colostrum, 0.9 mg/L to 25.1 mg/L for transitional
milk and 1.6 mg/L to 23.8 mg/L and mature milk, respectively.22–24
The total glycolipid content of the HM pool used in our study
ranged from 14.72 mg/L at time zero to 14.40 mg/L after 60 days
at RT. These values are in the middle-range of those reported for
mature HM. Individual GD3 and GM3 content (8.83–9.69 mg/L and
5.47–5.86 mg/L, respectively, for time zero and after 60 days at RT
and trends in our study reflected the published data, with GM3
being the dominant species and GD3 showing lower values.
Similarly, we found that none of the heat treatments significantly
altered the content of individual or total gangliosides, with the
exception of HT-2, where a statistically significant increase in GM3
was observed. The evaluation of the effect of heat treatment and
storage temperature showed that neither significantly affected
ganglioside content during 90 days of treatment (Fig. 1). However,
heat treatment caused the changes in both total and individual
ganglioside contents. HT-2 increased the content of GM3, GD3,
and total gangliosides compared with unheated milk, and HT-4
increased total gangliosides compared with unheated milk (Fig. 1).
Ceramides are the core structure of sphingolipids, which are
ubiquitous components of eukaryotic cell membranes and play
several roles in the human body: apoptosis, neuronal develop-
ment and membrane formation and stabilization.25 Classically,
gangliosides are considered biologically active because of their
oligosaccharide chain. However, nowadays the ceramide moiety is
gaining more attention thanks to recent studies demonstrating
that glycolipids’ effects are not only depending on their
oligosaccharide chain, but also on the ceramide composition. As
an example, Martín et al.26 reported that enterotoxigenic E. coli
(ETEC) strains bind to gangliosides in a ceramide-dependent
process and its adhesion properties changed with different
sphingoid base and fatty acid composition; whereas, the
oligosaccharide moiety remained unchanged. In another study,
Ladisch et al.27 reported that monosialogangliosides with short
and medium chain fatty acids (d18:1-C2:0-GM3 and d18:1-C14:0-
GM3) were more immunosuppressive than those with long-chain
fatty acids (d18:1-C18:0-GM3 and d18:1-C24:0-GM3). These studies
suggest that glycolipid ceramides play an active role in their
biological activity, although, scarce studies have been carried out
for a deeper evaluation of their individual activity. Although,
glycolipid content does not change during storage and is not
affected by heat treatments, their molecular species shifted,
varying the abundance of their ceramides (Figs. 2 and 3). These
modifications may modulate their biological activity, and point to
the need for more in-depth studies to evaluate the direction of
these changes.
Milk gangliosides are almost totally contained within the milk
fat globule membrane, with their ceramide component forming
part of the lipid bilayer. In this study, there were no significant
modifications in milk fat globule membrane content for ganglio-
sides, likely due to the lack of homogenization, as that step is not
part of the conventional processing of donor milk. Evidence
suggests human milk homogenization can increase fat absorption
and weight gain in preterm infants28 and drastically changes the
organization of milk components and decreases the size of milk
fat globules,29 possibly increasing gangliosides accessibility.
Therefore, alterations to milk fat globule structure could lead to
increased ganglioside release, rendering these compounds are
more vulnerable to heat treatment with consequent modifications
in their digestibility and/or bioavailability, as well as their
biological activity. Considering these factors, future studies on
human milk should consider the effect of biological effects of
homogenization relative to its industrial application.
CONCLUSIONS
This study evaluated the effects of different pasteurization
conditions and storage conditions on the composition and
quantity of the most abundant human milk gangliosides (GM3,
Fig. 1 Effect of heat treatment and storage time on human milk gangliosides (GM3, GD3, Total, GG). Multiple analysis of variance using HSD-
Tukey was used as a post hoc analysis test (p < 0.05). Results are expressed as mean ± standard deviation (n= 3). * Indicate statistical
differences with non-treated milk No heat treatment: pooled human milk sample not subjected to any heat treatment
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GD3). Our results demonstrate that the ganglioside content of
pasteurized human milk at 60 °C/30 min, and 127 °C for 5 s,
remains stable up to 90 days when stored at either refrigerator or
RT, even though minor structural changes occur depending on the
specific heat treatment. This type of study, if extended to more
classes of bioactive components, will be useful to characterize and
define ideal processing and storage conditions for donor milk and
help preserve the structure and functionality of these bioactive
compounds, with the final goal of enhancing fragile newborn
health. At the same time, broader and more standardized
annotation of bioactive food components will provide a platform
for computing the ways in which processing and storage
conditions alter or maintain the nutritive, bioactive, and organo-
leptic properties of ingredients and foods, as well as the
qualitative effects these foods and ingredients may have on
conferring health phenotypes in the consuming organism. Follow-
up work constructing standardized ontologies to capture this
knowledge and make it queriable is imminent.
MATERIALS AND METHODS
Reagents
High-performance liquid chromatography (HPLC)/MS grade methanol,
acetic acid, and isopropyl alcohol were purchased from Sigma (St. Louis,
MO, USA), and certified ACS grade chloroform came from Fisher (Fair Lawn,
NJ, USA). Ammonium acetate was of analytical reagent grade and was
acquired from Merck (Darmstadt, Germany), and C8 cartridges were
obtained from Supelco (Bellefonte, PA). The N-omega-CD3-octadecanoyl
GM3 (IS), and GM3 and GD3 ganglioside standards from buttermilk were
purchased from Matreya (Pleasant Gap, PA, USA). The stock solutions of
both standards were prepared separately in methanol to obtain a
concentration of 1 mg/mL. Milli-Q grade water was used for all
experiments.
Samples
Individual human milk samples from five healthy women between 90 and
180 days of lactation were collected using breast pumps, placed in sterile
polypropylene containers, immediately frozen at –20 °C, and sent to
Prolacta Bioscence, where they were stored at –30 °C. Once all samples for
the study were collected, they were sent to the UC Davis facilities for
analysis and processing. The sample temperature remained at –30 °C for a
maximum 1 month until the experiments were carried out.
All donors gave written informed consent to use the donated milk for
research purpose and the study was approved by the University of
California-Davis Ethics Committee.
Pasteurization treatments
Prior to pasteurization treatments, individual human milk samples were
defrosted and pooled. The pooled sample was used as starting materials
Fig. 2 Variation of GM3 species before and after heat treatment (time zero), and after 3 months storage at 4 or 25 °C. A GM3 standard (0.1 mg/
L) is also shown. HT-1 Holder pasteurization (63 °C/30min), HT-2 standard high-temperature-short-time pasteurization (72 °C/15 s), HT-3
extended shelf-life protocol (127 °C/5 s), HT-4 ultrahigh-temperature pasteurization (140 °C/6 s). No heat treatment: pooled human milk
sample not subjected to any heat treatment
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for all the treatments. Four different pasteurization treatments typically
employed in industry were applied to pooled human milk at the UC Davis
Milk Processing Lab using a UHT/HTST Lab 25 EHV hybrid continuous
pasteurizer with touch screen control and a combined sterile product
outlet/automatic filling control (SPO-AFC, MicroThermics, Raleigh, NC,
USA). Heat treatment 1 (HT-1) conditions were those described for classical
Holder pasteurization (63 °C for 30min); heat treatment 2 (HT-2) consisted
of a standard HTST and a holding temperature of 72 °C for 15 s; heat
treatment 3 (HT-3) conditions resembled an ESL protocol, wherein milk
was pasteurized for 5 s at 127 °C; heat treatment 4 (HT-4) was an UHT
pasteurization (140 °C for 6 s). The heat-treated human milk was collected
from the sterile product outlet in a high efficiency particulate air (HEPA)-
filtered laminar flow cabinet into autoclaved containers. Each heat
treatment was used to process 5 L of the human milk pool, with a result
of 4 L of heat-treated milk being divided into aliquots of 14mL for the
storage study.
For each pasteurization treatment human milk aliquots were split into
three groups: time zero, storage at RT, and cold storage (CS). The time-zero
samples were processed on the same day as the heat treatment was
carried out. RT samples were stored in a room with temperature and
relative humidity (RH) fixed at 23 °C and 40%, respectively, while CS
samples were stored at 4 °C. Samples were analyzed on days 0, 7, 30, 60,
and 90 after heat treatment for both storage conditions (Suppl. Figure 1).
Samples were stored away from direct light for the duration of the stability
study.
Glycolipid extraction
Samples were thawed and mixed in a water bath at 30 °C before
ganglioside extractions. Gangliosides were extracted as described else-
where with minor modifications.21 Briefly, gangliosides were separated
from neutral lipids by two consecutive extractions: 2 mL of milk sample
was mixed with methanol/chloroform/water (4:2:1 v/v/v), sonicated for
10min, and centrifuged for 5 min at 8800×g at 4 °C. Two milliliters of water
were added for phase separation and the aqueous phase was collected.
The lipid phase was re-extracted with 11mL of methanol/chloroform/water
(2:1:0.7 v/v/v) following the same procedure. The lipid phase was extracted
using 0.1 M KCl instead of water. The combined aqueous supernatants
were dried in a SpeedVac rotor concentrator (Savant Instruments Inc.,
Holbrook, NY, USA) and the lyophilized sample was resuspended in 1mL of
the methanol/water (1/1 v/v) solution.
The ganglioside extract was purified by C8 solid-phase extraction
(SPE).21 An SPE cartridge was conditioned with 5mL of the
methanol–water (1:1, v/v) solution, the sample was loaded and
washed by 5mL of the same methanol–water (1:1, v/v) solution, and
gangliosides were eluted with 10mL of isopropyl alcohol−methanol
(1:1, v/v) solution. The ganglioside eluate was divided into aliquots of
500 μL, an internal standard (IS) was added to obtain a final
concentration of 1 mg/mL, and the sample was dried under vacuum and
stored at –20 °C. Before the analysis, samples were redissolved in
50mL of methanol.
Fig. 3 Variation of GD3 species before and after heat treatment (time zero), and after 3 months storage at 4 or 25 °C. A GM3 standard (0.1 mg/
L) is also shown. HT-1 Holder pasteurization (63 °C/30min), HT-2 standard high-temperature-short-time pasteurization (72 °C/15 s), HT-3
extended shelf-life protocol (127 °C/5 s), HT-4 ultrahigh-temperature pasteurization (140 °C/6 s). No heat treatment: pooled human milk
sample not subjected to any heat treatment
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Ultrahigh-performance liquid chromatography–tandem mass
spectrometry (UHPLC–MS/MS)
To quantify gangliosides, an UHPLC–MS/MS method was employed in an
Agilent 1290 Infinity LC (Agilent, Santa Clara, CA, USA), equipped with an
Agilent Eclipse Plus C18 rapid resolution high-definition analytical column
(i.d. 2.1 × 100mm, 1.8 μm, 80 Å) for UHPLC separation. The column was
maintained at 50 °C and compounds were eluted using a gradient of 80
−90% solvent B from 0 to 0.2 min, then 90–100% for 2min; 100% of B was
maintained for 1 min, and the column was re-equilibrated for a 1-min post
run. Solvent A consisted of water and solvent B was 15% isopropyl alcohol
in methanol (v/v). Both solvents contained 20mM ammonium acetate and
0.1% acetic acid. The flow rate was 600 μL/min. Analytes were detected
and quantified in an Agilent 6490 triple quadrupole mass spectrometer,
operated in the negative electrospray ionization mode. The Agilent Jet
Stream electrospray ionization source was set for high sensitivity. The
drying gas temperature and flow were 250 °C and 12 L/min, respectively.
Sheath gas temperature and flow were 300 °C and 12 L/min, respectively.
The nebulizer gas pressure was set at 35 psi, and the capillary voltage was
set at 4000 V. The collision cell accelerator voltage was set to 5 V, and the
collision energy was optimized on a compound-dependent basis. Nitrogen
was used as the collision gas. The resolutions of the Q1 and Q3
quadrupoles were set at the unit resolution. The Agilent Data Acquisition
software was used to program the method and for data acquisition. The
Agilent MassHunter Qualitative Analysis and Quantitative Analysis Software
(v.B.03.01) were used for data processing.
The calibration curves used for quantification were 0, 0.5, 1, 1.5, and
2mg/L for GD3 and 0, 0.05, 0.1, 0.15, and 0.25mg/L for GM3. Samples were
redissolved in 50 μL of methanol immediately before being injected into
the system. The monitored transitions, the optimized collision energies,
and retention times are shown in Supplementary Table 1.
Each glycolipid (GM3, GD3) was quantified by summing the area ratio
(glycolipid/IS) of all their different species, and interpolating in the
calibration curve as shown in the equation:
GM3½  ¼ ΣGM3areaað Þ=b;
where “a” is the intercept and “b” is the slope of its calibration curve.
Statistical analysis
Normal data distribution was evaluated by the Kolmogorov–Smirnov test
(p < 0.05) and homoscedasticity was checked by Levene's test. A one-way
analysis of variance (ANOVA) was carried out to evaluate the direct effect
of each heat treatment on ganglioside content. A three-way ANOVA was
employed to assess the effect heat treatment, storage time, and
temperature on glycolipid content. The Tukey test was applied to assess
the differences between groups. Version 19.0.1 of the SPSS statistical
package for Macintosh (SPSS Inc., Chicago, IL, USA) was used throughout.
The methods were performed in accordance with relevant regulations
and guidelines.
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